Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Feuille

Pediatric Allergy/Immunology Los Angeles, CA Medical Doctor

NPI 1447549019 CMS profile 2788272

2080 Century Park E Ste 810, Los Angeles, CA 90067

Open in the dashboard

General payments

$5,559

234 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Feuille of Los Angeles, CA is reported in the CMS Open Payments database as having received $5,559 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,734 62
2024 General $1,593 62
2023 General $1,357 65
2022 General $875 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Feuille
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Elizabeth Feuille were reported at $1,734. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Elizabeth Feuille Pediatric Allergy/Immunology median Middle half National median
2019 $0 $325 $92–$1,399 $163
2020 $0 $144 $66–$2,490 $114
2021 $0 $357 $95–$2,633 $132
2022 $875 $385 $125–$2,259 $149
2023 $1,357 $470 $121–$2,946 $160
2024 $1,593 $317 $125–$2,583 $164
2025 $1,734 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Regeneron Healthcare Solutions, Inc. $1,397 54 payments
  2. GlaxoSmithKline, LLC. $840 27 payments
  3. Genzyme Corporation $447 11 payments
  4. Pfizer Inc. $394 23 payments
  5. AbbVie, Inc. $367 28 payments
  6. Novartis Pharmaceuticals Corporation $344 13 payments
  7. AstraZeneca Pharmaceuticals LP $292 14 payments
  8. CSL Behring $265 12 payments
  9. Hikma Pharmaceuticals USA $204 10 payments
  10. Amgen Inc. $188 8 payments
  11. Other $821 34 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,559 234 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT Inflammation And Immunology $1,088 44 payments
  2. NUCALA $517 14 payments
  3. DUPIXENT Immunology $487 13 payments
  4. CIBINQO $394 23 payments
  5. RINVOQ $367 28 payments
  6. TRELEGY ELLIPTA $323 13 payments
  7. EUCRISA $287 18 payments
  8. Hizentra $232 11 payments
  9. Ryaltris $204 10 payments
  10. DUPIXENT Immunology And Inflammation $189 9 payments
  11. Other $1,823 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$5,383

Medicare's payments for the services billed

Medicare patients

19

Average age 74

Services billed

257

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 63%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $590
  • GENZYME CORPORATION $200
$790 — —
NUCALA
  • GlaxoSmithKline, LLC. $116
$116 — —
CIBINQO
  • PFIZER INC. $104
$104 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $96
$96 — —
EUCRISA
  • PFIZER INC. $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record